Wasatch Advisors LP Makes New $7.68 Million Investment in Immatics (NASDAQ:IMTX)

Wasatch Advisors LP purchased a new position in Immatics (NASDAQ:IMTX) during the first quarter, HoldingsChannel.com reports. The fund purchased 730,394 shares of the company’s stock, valued at approximately $7,676,000.

A number of other large investors have also added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Immatics by 13.3% in the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after acquiring an additional 747,772 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Immatics by 324.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock worth $16,310,000 after acquiring an additional 1,183,860 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Immatics in the 4th quarter worth $232,000. Superstring Capital Management LP bought a new stake in Immatics in the 4th quarter worth $834,000. Finally, Platinum Investment Management Ltd. grew its holdings in Immatics by 16.9% in the 4th quarter. Platinum Investment Management Ltd. now owns 313,574 shares of the company’s stock worth $3,302,000 after acquiring an additional 45,363 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Mizuho raised their target price on shares of Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th.

Immatics Stock Up 0.2 %

Shares of NASDAQ:IMTX traded up $0.02 on Tuesday, hitting $12.02. The company had a trading volume of 339,608 shares, compared to its average volume of 520,243. The firm’s 50-day simple moving average is $11.57 and its two-hundred day simple moving average is $11.38. Immatics has a 1 year low of $7.15 and a 1 year high of $13.77. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -11.34 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last posted its earnings results on Tuesday, May 14th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.70. Immatics had a negative net margin of 107.80% and a negative return on equity of 29.36%. The firm had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $17.76 million. Equities research analysts anticipate that Immatics will post -1.26 EPS for the current year.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.